CoChat

Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy

Open access
Huang, Jau-Ling, Chang, Yu-Tzu, Hong, Zhen-Yang, Lin, Chang-Shen · 2022 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index.

Abstract

Deficiency in DNA damage response (DDR) genes leads to impaired DNA repair functions that will induce genomic instability and facilitate cancer development. However, alterations of DDR genes can serve as biomarkers for the selection of suitable patients to receive specific therapeutics, such as immune checkpoint blockade (ICB) therapy. In addition, certain altered DDR genes can be ideal therapeutic targets through adapting the mechanism of synthetic lethality. Recent studies indicate that targeting DDR can improve cancer immunotherapy by modulating the immune response mediated by cGAS-STING-interferon signaling. Investigations of the interplay of DDR-targeting and ICB therapies provide more effective treatment options for cancer patients. This review introduces the mechanisms of DDR and discusses their crucial roles in cancer therapy based on the concepts of synthetic lethality and ICB. The contemporary clinical trials of DDR-targeting and ICB therapies in breast, colorectal, and pancreatic cancers are included.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms23063238

Cites

154 of 154 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Cancer hallmarks, target therapy and immunotherapy. (A) Hallmarks and enabling characteristics of cancer. Hanahan and Weinberg propose six fundamental hallmarks (autonomous growth signal, evasion of growth inhibitory signal, evasion of apoptosis cell death, unlimited replicative potential, angiogenesis, and invasion and metastasis), two emerging hallmarks (reprogram energy metabolism and avoiding immune destruction), and two enabling characteristics (genomic instability and tumor-promoting inflammation) to distinguish cancer from normal cells. The genomic instability and avoiding immune destruction (in red) are the principal foundations of synthetic lethality and immune checkpoint blockade-based cancer therapy. (B) Target therapy and immunotherapy. (Left part) The epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) are the major targets of tyrosine kinase inhibitors (TKI), such as HerceptinTM (trastuzumab) and AvastinTM (Bevacizumab). (Right part) The CTLA-4, PD-1, and PD-L1 are immune checkpoint molecules (in red) for cancer immunotherapy. The immune checkpoint inhibitors (ICI) include ipilimumab (anti-CTLA-4 antibody), nivolumab and pembrolizumab (anti-PD-1 antibody), and atezolizumab, avelumab and durvalumab (anti-PD-L1 antibody). Ag, antigen. APC, antigen presenting cells. CTL, cytotoxic T lymphocyte. MHC, major histocompatibility complex. TCR, T-cell receptor. Graph created with Biorender.com.
Figure 1 Cancer hallmarks, target therapy and immunotherapy. (A) Hallmarks and enabling characteristics of cancer. Hanahan and Weinberg propose six fundamental hallmarks (autonomous growth signal, evasion of growth inhibitory signal, evasion of apoptosis cell death, unlimited replicative potential, angiogenesis, and invasion and metastasis), two emerging hallmarks (reprogram energy metabolism and avoiding immune destruction), and two enabling characteristics (genomic instability and tumor-promoting inflammation) to distinguish cancer from normal cells. The genomic instability and avoiding immune destruction (in red) are the principal foundations of synthetic lethality and immune checkpoint blockade-based cancer therapy. (B) Target therapy and immunotherapy. (Left part) The epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) are the major targets of tyrosine kinase inhibitors (TKI), such as HerceptinTM (trastuzumab) and AvastinTM (Bevacizumab). (Right part) The CTLA-4, PD-1, and PD-L1 are immune checkpoint molecules (in red) for cancer immunotherapy. The immune checkpoint inhibitors (ICI) include ipilimumab (anti-CTLA-4 antibody), nivolumab and pembrolizumab (anti-PD-1 antibody), and atezolizumab, avelumab and durvalumab (anti-PD-L1 antibody). Ag, antigen. APC, antigen presenting cells. CTL, cytotoxic T lymphocyte. MHC, major histocompatibility complex. TCR, T-cell receptor. Graph created with Biorender.com.CC BY · PubMed Central
Figure 2 (A) DNA repair systems. Different DNA damages are recognized and repaired through different DNA repair pathways. DNA damages shown here includes ultraviolent light (UV)-induced cyclobutane pyrimidine dimers (TT), benzo[a]pyrene (BaP)-induced bulky DNA adducts, DNA interstrand crosslink, deamination (-NH3, GC to GU pairing), reactive oxygen species (ROS) induced 8-oxoguanine, mismatch DNA pairing (e.g., AG pairing), double-strand breaks (DSBs) induced by ionized radiation, X-ray or cisplatin. Except for direct repair, nucleotide excision repair (NER), base excision repair (BER), mismatch repair (MMR), homologous recombination (HR) and non-homologous end-joining (NHEJ) are shown here. Each DNA repair mechanism comprises three main procedures: recognition, excision, and polymerization. The red circle indicates the defective mutations found in hereditary nonpolyposis colorectal cancer (HNPCC), colorectal cancer (CRC), breast cancer (BC), ovary cancer (OC) and pancreatic cancer (PC). (B) The DNA damage response (DDR). ATM and ATR are activated by DSBs and single-strand breaks. The activated ATM and ATR phosphorylate downstream cell cycle checkpoint kinases, CHK1 and CHK2, which then phosphorylate p53, CDC25, and WEE1. The phosphorylated p53 increases the expression of p21, a potent CDK inhibitor. Phosphorylation of CDC25 (inactive) and WEE1 (active) results in inhibition of CDK activity and leads to cell cycle arrest at G1/S and G2/M transition. Graph created with Biorender.com.
Figure 2 (A) DNA repair systems. Different DNA damages are recognized and repaired through different DNA repair pathways. DNA damages shown here includes ultraviolent light (UV)-induced cyclobutane pyrimidine dimers (TT), benzo[a]pyrene (BaP)-induced bulky DNA adducts, DNA interstrand crosslink, deamination (-NH3, GC to GU pairing), reactive oxygen species (ROS) induced 8-oxoguanine, mismatch DNA pairing (e.g., AG pairing), double-strand breaks (DSBs) induced by ionized radiation, X-ray or cisplatin. Except for direct repair, nucleotide excision repair (NER), base excision repair (BER), mismatch repair (MMR), homologous recombination (HR) and non-homologous end-joining (NHEJ) are shown here. Each DNA repair mechanism comprises three main procedures: recognition, excision, and polymerization. The red circle indicates the defective mutations found in hereditary nonpolyposis colorectal cancer (HNPCC), colorectal cancer (CRC), breast cancer (BC), ovary cancer (OC) and pancreatic cancer (PC). (B) The DNA damage response (DDR). ATM and ATR are activated by DSBs and single-strand breaks. The activated ATM and ATR phosphorylate downstream cell cycle checkpoint kinases, CHK1 and CHK2, which then phosphorylate p53, CDC25, and WEE1. The phosphorylated p53 increases the expression of p21, a potent CDK inhibitor. Phosphorylation of CDC25 (inactive) and WEE1 (active) results in inhibition of CDK activity and leads to cell cycle arrest at G1/S and G2/M transition. Graph created with Biorender.com.CC BY · PubMed Central
Figure 3 (A) Synthetic lethality by BRCAness and PARPness. The core structure (phthalazinones) of PARP inhibitor olaparib is shown in red. Inhibition of PARP in cancer cells harboring BRCA1/2 mutation or homologous recombination repair deficient (HRD) phenotype leads to DNA double-strand breaks (DSBs) and cell apoptosis. This condition is PARP sensitive (PARPness) (left part). Auto-PARylation of PARP is essential for base excision repair and DSB repair to survive (central part). (B) Synthetic lethality beyond BRCAness and PARPness. PARP inhibitor increases cell apoptosis in cisplatin or radiotherapy sensitive cancers, suggesting that PARP inhibitor can be a sensitizer of cisplatin and ionizing radiation. Graph created with Biorender.com.
Figure 3 (A) Synthetic lethality by BRCAness and PARPness. The core structure (phthalazinones) of PARP inhibitor olaparib is shown in red. Inhibition of PARP in cancer cells harboring BRCA1/2 mutation or homologous recombination repair deficient (HRD) phenotype leads to DNA double-strand breaks (DSBs) and cell apoptosis. This condition is PARP sensitive (PARPness) (left part). Auto-PARylation of PARP is essential for base excision repair and DSB repair to survive (central part). (B) Synthetic lethality beyond BRCAness and PARPness. PARP inhibitor increases cell apoptosis in cisplatin or radiotherapy sensitive cancers, suggesting that PARP inhibitor can be a sensitizer of cisplatin and ionizing radiation. Graph created with Biorender.com.CC BY · PubMed Central
Figure 4 Cytosolic DNA sensing by cGAS-STING is crucial for immunotherapy. Ionizing radiation (IR), mismatch repair deficiency (dMMR), and PARP inhibitor-induced synthetic lethality (PARPness) in cancer cells induce DNA damage that increase micronuclei (MN) and amounts of cytosolic DNA. The cyclic GMP-AMP synthase (cGAS) binds to cytosolic DNA and produces cyclic-dinucleotide, 2′3′-cGAMP (cGAMP), which activates the stimulator of interferon genes (STING), allowing STING translocation from endoplasmic reticulum to Golgi apparatus to activate interferon regulatory factor 3 (IRF3) and NF-κB through the TANK-binding kinase 1 (TBK1) and IKKα/β. The activated IRF3 and NF-κB go into nucleus to turn on expression of interferon α/β (IFNα/β) and TNF-α through interferon–stimulated responsive element (ISRE) and NF-κB responsive element. IFNα/β bind to interferon receptor (IFNR1/2) to activate JAK/STAT signaling and produce interferon-stimulated genes (ISGs), IFNγ, and IP-10, which can activate and attract CD8+ T cells migration from lymph nodes to tumor microenvironment to kill cancer cells via FAS/FASL and TRAIL/TRAILR interactions. Graph created with Biorender.com.
Figure 4 Cytosolic DNA sensing by cGAS-STING is crucial for immunotherapy. Ionizing radiation (IR), mismatch repair deficiency (dMMR), and PARP inhibitor-induced synthetic lethality (PARPness) in cancer cells induce DNA damage that increase micronuclei (MN) and amounts of cytosolic DNA. The cyclic GMP-AMP synthase (cGAS) binds to cytosolic DNA and produces cyclic-dinucleotide, 2′3′-cGAMP (cGAMP), which activates the stimulator of interferon genes (STING), allowing STING translocation from endoplasmic reticulum to Golgi apparatus to activate interferon regulatory factor 3 (IRF3) and NF-κB through the TANK-binding kinase 1 (TBK1) and IKKα/β. The activated IRF3 and NF-κB go into nucleus to turn on expression of interferon α/β (IFNα/β) and TNF-α through interferon–stimulated responsive element (ISRE) and NF-κB responsive element. IFNα/β bind to interferon receptor (IFNR1/2) to activate JAK/STAT signaling and produce interferon-stimulated genes (ISGs), IFNγ, and IP-10, which can activate and attract CD8+ T cells migration from lymph nodes to tumor microenvironment to kill cancer cells via FAS/FASL and TRAIL/TRAILR interactions. Graph created with Biorender.com.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 43

Metadata

Authors
Huang, J.-L., Chang, Y.-T., Hong, Z.-Y., & Lin, C.-S.
Affiliations
  • Chang Jung Christian University (TW)
  • National Sun Yat-sen University (TW)
Corresponding author
Lin, Chang-Shen
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-03-17
Volume
23
Issue
6
Pages
3238
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4221000214
Cited by
42
References
154
Citations by year
2026: 7 · 2025: 15 · 2024: 6 · 2023: 8 · 2022: 6
FWCI
1.10
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Ministry of Science and Technology, Taiwan (108-2635-B-309-001 and 110-2320-B-037-023. The APC was funded by 110-2320-B-037-023”)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords
DNA damage response, immune checkpoint blockade, synthetic lethality, cancer immunotherapy, cGAS-STING pathway, interferon signaling, genomic instability, breast cancer, colorectal cancer, pancreatic cancer
MeSH terms
DNA Damage, DNA Repair, Humans, Immunity, Immunotherapy, Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.